

## CORRECTION

# Correction to: a Phase 2 Study of $16\alpha$ -[ $^{18}\text{F}$ ]-Fluoro- $17\beta$ -Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

Lanell M. Peterson,<sup>1</sup> Brenda F. Kurland,<sup>2,3</sup> Erin K. Schubert,<sup>1,4</sup> Jeanne M. Link,<sup>5</sup> V. K. Gadi,<sup>2,6</sup> Jennifer M. Specht,<sup>2,6</sup> Janet F. Eary,<sup>5</sup> Peggy Porter,<sup>2</sup> Lalitha K. Shankar,<sup>7</sup> David A. Mankoff,<sup>1,4</sup> Hannah M. Linden<sup>2,6</sup>

<sup>1</sup>Radiology/Nuclear Medicine, University of Washington Medical Center–Seattle Cancer Care Alliance, Seattle, WA, USA

<sup>2</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

<sup>3</sup>Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA

<sup>4</sup>Radiology/Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, USA

<sup>5</sup>Radiology/Nuclear Medicine, University of Washington Medical Center, Seattle, WA, USA

<sup>6</sup>Medical Oncology, University of Washington Medical Center–Seattle Cancer Care Alliance, Seattle, WA, USA

<sup>7</sup>Cancer Imaging Program, National Cancer Institute, Bethesda, MD, USA

### Correction to: Mol Imaging Biol

<https://doi.org/10.1007/s11307-013-0699-7>

Two data points from Table 1. (continued) were published in error. The corrected data in Table 1. (continued) are shown, in *italic*.

**Table 1.** (continued)

| Patients ( <i>n</i> = 19)           | N (%) or median (min-max) |
|-------------------------------------|---------------------------|
| HER2neu (metastatic lesion)         |                           |
| Positive                            | 3 (20 %)                  |
| Negative                            | 8 (53 %)                  |
| Unknown                             | 4 (27 %)                  |
| Clinical response                   |                           |
| Partial response                    | 4 (21 %)                  |
| Stable disease                      | 4 (21 %)                  |
| Radiographic progressive disease    | 7 (37 %)                  |
| No response assessment <sup>c</sup> | 4 (21 %)                  |

<sup>a</sup>One patient also underwent ovarian suppression

<sup>b</sup>When Allred scores were available, scoring was 0 “negative,” 2–6 “weakly positive,” 7–8 “positive.” When Allred scores were not available, clinical report scores of 1+ were “weakly positive”

<sup>c</sup>Includes two patients who did not undergo endocrine monotherapy, one who had complications from a non-breast cancer-related surgery after 2 days of anastrozole, and one who changed therapy (from tamoxifen) when a successful metastatic biopsy revealed ER- disease

The online version of the original article can be found at <https://doi.org/10.1007/s11307-013-0699-7>

Correspondence to: Lanell Peterson; e-mail: lanell@uw.edu